Literature DB >> 2442538

A comparison of hypotensive responses after oral and intravenous administration of enalapril and lisinopril in chronic heart failure.

K Dickstein, T Aarsland, K Tjelta, V J Cirillo, H J Gomez.   

Abstract

The acute hypotensive response to oral and parenteral enalapril (E) and lisinopril (LI) was assessed in 24 patients with chronic congestive heart failure in two open, randomized, balanced, crossover studies. In the E study, 12 patients received each of three treatments: a single oral dose of 10 mg E, a single intravenous bolus of 5 mg E, and a single intravenous bolus of 5 mg enalaprilat (ET). In the LI study, 12 patients received each of two treatments: a single oral dose of 10 mg LI and a single intravenous bolus of 5 mg LI. Intraarterial blood pressure was measured continuously. Significant decreases from baseline in mean arterial pressure (MAP) were observed in all cases, starting at 15 min. The maximal hypotensive effect (MAP; mean +/- SD) was greatest and the nadir earliest for intravenous ET (-30 +/- 7 mm Hg at 75 min) compared with oral E (-25 +/- 10 mm Hg at 210 min) and intravenous E (-19 +/- 10 mm Hg at 195 min). Oral E and intravenous E had similar onsets of action. The maximal reduction following oral LI (-19 +/- 13 mm Hg at 210 min) was similar to oral E and intravenous E. The effect of intravenous LI (-25 +/- 9 mm Hg at 105 min) was similar to that of intravenous ET. Among the parenteral treatments, E produced the most gradual and least pronounced reduction in blood pressure, and may be best suited for use in the acute situation to minimize the risk of abrupt hypotension.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442538     DOI: 10.1097/00005344-198706000-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension.

Authors:  A H Thomson; J G Kelly; B Whiting
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

Review 2.  Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

Review 3.  Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  S G Lancaster; P A Todd
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

4.  The pharmacokinetics of lisinopril in hospitalized patients with congestive heart failure.

Authors:  A E Till; K Dickstein; T Aarsland; H J Gomez; H Gregg; M Hichens
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

5.  [Conversion from oral ACE inhibitor to intravenous quinaprilat administration in mild to moderate essential hypertension].

Authors:  B M Schmidt; J Smilde; C Oldenbroek; M Wehling
Journal:  Med Klin (Munich)       Date:  1998-12-15

6.  Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br Heart J       Date:  1993-04

7.  Acute hemodynamic effects of converting enzyme inhibition in children with intracardiac shunts.

Authors:  M W Webster; J M Neutze; A L Calder
Journal:  Pediatr Cardiol       Date:  1992-07       Impact factor: 1.655

8.  Fast parameters estimation in medication efficacy assessment model for heart failure treatment.

Authors:  Yinzi Ren; Xiao Fu; Qing Pan; Chengyu Lin; Guiqiu Yang; Li Li; Shijin Gong; Guolong Cai; Jing Yan; Gangmin Ning
Journal:  Comput Math Methods Med       Date:  2012-10-03       Impact factor: 2.238

9.  Isolated circulatory response to intravenous administration of the ACE inhibitor enalaprilat.

Authors:  J Boldt; C Knothe; F Schindler; W A Stertmann; G Hempelmann
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.